trial
as of 2026-07-01Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
NCTId NCT02417142
at a glance
Phase 4 · Completed
Enrollment 70 (actual)
Sponsored by University of Massachusetts, Worcester
Primary completion 2019-07
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
70 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2014-09
Primary completion
2019-07
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
University of Massachusetts, WorcesterLead Sponsor
Stanley Medical Research InstituteCollaborator
Investigators
1
Xiaoduo Fan, MD, MPH, MSPrincipal Investigator
Sites
1 total
Worcester, United States
Facts & assertions
4 sourced
Enrollment
70
Phase
PHASE4
Primary Completion Date
2019-07
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
investigator
person